强化筛查项目对HIV感染者非艾滋病定义肿瘤检出影响的研究
本研究为多中心、非盲、随机对照试验,比较常规筛查与强化筛查在HIV感染者中早期诊断非艾滋病定义肿瘤的效果。强化组针对肺癌、肝癌、肛门癌、宫颈癌、乳腺癌、前列腺癌、结直肠癌和皮肤癌进行扩展筛查。主要比较早期癌症诊断频率、安全性、成本效用及非艾滋病定义肿瘤的总体和部位特异性发病率。
要点
- 多中心非盲随机对照试验,比较常规筛查与强化筛查在HIV感染者中的效果。
- 强化筛查覆盖肺癌、肝癌、肛门癌、宫颈癌、乳腺癌、前列腺癌、结直肠癌和皮肤癌。
- 主要目标包括早期癌症诊断频率、安全性、成本效用及非艾滋病定义肿瘤发病率。
核心结论
- 强化非艾滋病定义肿瘤筛查项目可能实现早期诊断并改善HIV感染者的预后,且不必要干预率可接受,但在实施前必须证明获益明确大于危害。
研究设计与样本
- 多中心、非盲、随机对照试验,比较常规筛查与强化筛查两个平行组,研究在西班牙艾滋病研究网络队列(CoRIS)框架内进行。
临床怎么用
- 常规干预组遵循参与中心的标准化筛查,依据欧洲艾滋病临床学会(EACS)推荐。
- 强化干预组遵循扩展筛查,旨在早期发现肺癌、肝癌、肛门癌、宫颈癌、乳腺癌、前列腺癌、结直肠癌和皮肤癌。
局限性
- 目前尚无关于HIV感染者扩展癌症筛查策略的研究,估计此类项目成本效果或成本效用的可用数据稀缺。
- 在策略可实施前,必须证明获益明确大于危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of non-AIDS defining cancer (NADC) is higher in people living with HIV (PLWH) than in the general population, and it is already one of the leading causes of death in the HIV-infected population. It is estimated that the situation will be aggravated by the progressive aging of PLWH. Early diagnosis through intensive cancer screening may improve the ability for therapeutic interventions and could be critical in reducing mortality, but it might also increase expenditure and harms associated with adverse events. The aim of this study is to evaluate an enhanced screening program for early diagnosis of cancer in PLWH compared to standard practice. The specific objectives are (1) to compare the frequency of cancer diagnosed at an early stage, (2) to analyze safety of the enhanced program: adverse events and unnecessary interventions, (3) to analyze the cost-utility of the program, and (4) to estimate the overall and site-specific incidence of NADC in PLWH. METHODS: We will conduct a multicenter, non-blinded, randomized, controlled trial, comparing two parallel arms: conventional vs enhanced screening. Data will be recorded in an electronic data collection notebook. Conventional intervention group will follow the standard of care screening in the participating centers, according to the European AIDS Clinical Society recommendations, and the enhanced intervention group will follow an expanded screening aimed to early detection of lung, liver, anal, cervical, breast, prostate, colorectal, and skin cancer. The trial will be conducted within the framework of the Spanish AIDS Research Network Cohort (CoRIS). DISCUSSION: The trial will evaluate the efficacy, safety, and efficiency of an enhanced screening program for the early diagnosis of cancer in HIV patients compared to standard of care practice. The information provided will be relevant since there are currently no studies on expanded cancer screening strategies in patients with HIV, and available data estimating cost effectiveness or cost-utility of such as programs are scarce. An enhanced program for NADC screening in patients with HIV could lead to early diagnosis and improve the prognosis of these patients, with an acceptable rate of unnecessary interventions, but it is critical to demonstrate that the benefits clearly outweigh the harms, before the strategy could be implemented. TRIAL REGISTRATION: ClinicalTrials.gov NCT04735445. Registered on 25 June 2019.
引用
- Masiá M, Padilla S, Estañ G, et al. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection. Trials. 2021. PMID: 34838115. doi:10.1186/s13063-021-05777-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。